LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
LEXICON PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.55+0.03 (+1.97%)
Close on Oct 19, 2026
- Market cap
- $678.36M
- P/E (TTM)
- –
- Dividend yield
- –
Lexicon Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Lexicon Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $689.68M | $164.85M |
| Enterprise Value | $550.51M | $87.06M |
| PS Ratio | 16.63 | 3.60 |
| PB Ratio | 3.95 | 2.03 |
| P/TBV Ratio | 5.31 | 2.31 |
Enterprise value
| Measure | Lexicon Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 13.28 | 2.43 |
Income (trailing twelve months)
| Measure | Lexicon Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $41.47M | $57.94M |
| Gross Profit | $41.11M | $90.47M |
| Operating Income | -$54.50M | -$21.44M |
| Net Income | -$61.12M | -$22.46M |
| EBITDA | -$54.02M | -$16.91M |
| EPS (Diluted) | -$0.15 | -$0.83 |
Margins
| Measure | Lexicon Pharmaceuticals | Industry median |
|---|---|---|
| Gross Margin | 99.1% | 52.3% |
| Operating Margin | -131.4% | -44.5% |
| Profit Margin | -147.4% | -39.2% |
| EBITDA Margin | -130.3% | -31.3% |
Returns
| Measure | Lexicon Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -40.2% | -53.1% |
| Return on Assets (ROA) | -25.7% | -41.0% |
| Return on Invested Capital (ROIC) | -162.8% | -32.0% |
| Return on Capital Employed (ROCE) | -23.2% | -37.8% |
Growth
| Measure | Lexicon Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -29.0% | 6.01% |
| Revenue Growth (3Y CAGR) | 610.3% | 2.25% |
| Revenue Growth (5Y CAGR) | 15.7% | 6.42% |
Balance sheet
| Measure | Lexicon Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $190.61M | $62.42M |
| Total Debt | $51.44M | $120.13M |
| Net Cash (Debt) | $139.17M | $15.68M |
| Net Cash Per Share | $0.31 | $0.66 |
| Equity (Book Value) | $174.53M | $48.79M |
| Book Value Per Share | $0.39 | $1.36 |
| Tangible Book Value | $129.98M | $23.06M |
| Working Capital | $181.87M | $75.77M |
Financial position
| Measure | Lexicon Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 13.37 | 3.30 |
| Quick Ratio | 13.07 | 2.39 |
| Debt / Equity | 0.29 | 0.51 |
Cash flow (trailing twelve months)
| Measure | Lexicon Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$64.99M | -$12.35M |
Efficiency
| Measure | Lexicon Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.17 | 0.38 |
| Inventory Turnover | 0.52 | 2.67 |
| Revenue Per Employee | $511.96K | $398.96K |
| Profits Per Employee | -$754.53K | -$703.34K |
| Employee Count | 81 | 74 |
Dividends and yields
| Measure | Lexicon Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -8.86% | -22.7% |
Shares
| Measure | Lexicon Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 444,956,000 | 58,179,650 |
| Shares Change (YoY) | 7.99% | 11.1% |
| Shares Change (QoQ) | 4.97% | 0.54% |
| Shares Held by Institutions | 81.9% | 59.4% |
Scores
| Measure | Lexicon Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -5.68 | -0.24 |
| Piotroski F-Score | 4 | 4 |
| Beneish M-Score | -1.19 | -2.62 |
Calculated by StockData from Lexicon Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.